Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways

被引：3

作者：

Hoverman, J. Russell ^{[1
,2
]}

机构：

[1] Texas Oncol, US Oncol McKesson Specialty Hlth, Value Based Programs, Dallas, TX USA

[2] US Oncol McKesson Specialty Hlth, The Woodlands, TX USA

来源：

CANCER MEDICINE | 2020年 / 9卷 / 15期

关键词：

cancer management; chemotherapy; clinical cancer research; medical oncology; RANDOMIZED CONTROLLED-TRIALS; CELL LUNG-CANCER; AMERICAN SOCIETY; PHASE-III; SURVIVAL; COST; BEVACIZUMAB; CARBOPLATIN; QUALITY; MANAGEMENT;

D O I：

10.1002/cam4.3193

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value-based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value-based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value.

引用

页码：5306 / 5311

页数：6

共 55 条

[1] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer [J].

Aghajanian, Carol ;

Goff, Barbara ;

Nycum, Lawrence R. ;

Wang, Yan V. ;

Husain, Amreen ;

Blank, Stephanie V. .

GYNECOLOGIC ONCOLOGY, 2015, 139 (01) :10-16

[2]

[Anonymous], FDA GRANTS BEV FULL

[3]

ASCO Post Staff, FDA ONC DRUG APPR GR

[4] Evolution of the Randomized Controlled Trial in Oncology Over Three Decades [J].

Booth, Christopher M. ;

Cescon, David W. ;

Wang, Lisa ;

Tannock, Ian F. ;

Krzyzanowska, Monika K. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5458-5464

[5] Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings [J].

Booth, Christopher M. ;

Le Maitre, Aurelie ;

Ding, Keyue ;

Farn, Kristen ;

Fralick, Michael ;

Phillips, Cameron ;

Cescon, David W. ;

Meyer, Ralph M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) :3938-3944

[6] Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Non-squamous, Non-Small Cell Lung Cancer [J].

Brooks, Gabriel A. ;

Austin, Andrea M. ;

Uno, Hajime ;

Dragnev, Konstantin H. ;

Tosteson, Anna N. A. ;

Schrag, Deborah .

JAMA NETWORK OPEN, 2018, 1 (06)

[7] Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success? [J].

Chan, John K. ;

Ueda, Stefanie M. ;

Sugiyama, Valerie E. ;

Stave, Christopher D. ;

Shin, Jacob Y. ;

Monk, Bradley J. ;

Sikic, Branimir I. ;

Osann, Kathryn ;

Kapp, Daniel S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1511-1518

[8] A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) [J].

Cherny, N. I. ;

Sullivan, R. ;

Dafni, U. ;

Kerst, J. M. ;

Sobrero, A. ;

Zielinski, C. ;

de Vries, E. G. E. ;

Piccart, M. J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1547-1573

[9]

CMS, NAT HLTH EXP 2018 HI

[10] Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer [J].

Cohen, Joshua T. ;

Lin, Pei-Jung ;

Sheinson, Daniel M. ;

Wong, William B. ;

Wu, Ning ;

Yim, Yeun Mi ;

Ramsey, Scott D. .

JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (11) :595-+

← 1 2 3 4 5 6 →